Cellectis S.A. (NASDAQ:CLLS) Stock Short Interest Jumps 68.5%

Cellectis S.A. (NASDAQ:CLLS) was the target of a large increase in short interest in September. As of September 15th, there was short interest totaling 488,061 shares, an increase of 68.5% from the August 31st total of 289,689 shares. Approximately 0.6% of the shares of the stock are sold short. Based on an average daily volume of 207,376 shares, the days-to-cover ratio is presently 2.4 days.

Wall Street Analyst Weigh In

CLLS has been the topic of a number of research reports. Wells Fargo & Company decreased their target price on shares of Cellectis from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Tuesday, September 15th. Robert W. Baird lowered their price objective on Cellectis from $10.00 to $8.00 and set an “outperform” rating for the company in a research note on Tuesday, September 15th. Citizens Jmp restated a “market perform” rating on shares of Cellectis in a research report on Tuesday, September 15th. Weiss Ratings downgraded Cellectis from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. Finally, Barclays downgraded Cellectis from an “overweight” rating to an “underweight” rating and lowered their price objective for the stock from $9.00 to $1.30 in a research report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Cellectis has an average rating of “Hold” and an average price target of $5.46.

Cellectis Price Performance

Shares of NASDAQ CLLS opened at $1.45 on Thursday. Cellectis has a fifty-two week low of $1.25 and a fifty-two week high of $5.48. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.37 and a current ratio of 1.37. The stock has a market cap of $145.49 million, a price-to-earnings ratio of -2.32 and a beta of 2.92. The firm’s 50-day simple moving average is $2.67 and its 200 day simple moving average is $3.15.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.The company had revenue of $6.90 million during the quarter, compared to the consensus estimate of $11.05 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cellectis stock. Lido Advisors LLC acquired a new position in Cellectis S.A. (NASDAQ:CLLS) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. 63.90% of the stock is owned by institutional investors.

About Cellectis

Cellectis SA (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.